A Phase 2, Randomized, Multicenter, Masked, Parallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost-grenod (Primary) ; Latanoprost
Indications Ocular hypertension; Open-angle glaucoma
Focus First in man; Therapeutic Use
Acronyms Dolomites
Sponsors NicOx

Most Recent Events

01 Jun 2022 Results published in the Journal of Glaucoma
11 Apr 2022 Results presented in a NicOx Media Release.
11 Apr 2022 According to a NicOx media release, data published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight